Scribe Therapeutics prices upsized IPO at $15 per share, targets $128.7 million in proceeds
AI Market Summary
Scribe Therapeutics priced an upsized IPO at the top of the range ($15) and expects $128.7m gross proceeds, alongside a concurrent $7.5m private placement with Sanofi. The transaction highlights still-open risk appetite for early-stage biotech and gene-editing platforms, but with no commercial products or revenue, near-term market impact is likely contained to biotech sentiment and primary issuance dynamics rather than broader macro assets.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-2.47%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Scribe Therapeutics (Nasdaq: SCTX) said on July 23, 2026 it priced an upsized initial public offering of 8,580,000 shares at $15.00 per share, expecting gross proceeds of $128.7 million. The shares are slated to begin trading on the Nasdaq Global Market on July 24, 2026 under the symbol “SCTX.” The company also agreed to sell 500,000 shares at $15.00 per share in a concurrent private placement to Sanofi. Scribe is a clinical-stage CRISPR gene-editing biotechnology company focused on cardiometabolic disease and does not have a marketed product or revenue.
